FDA Approves Once-Weekly Efsitora Insulin for Type 2 Diabetes Management
The United States Food and Drug Administration (FDA) has granted approval for efsitora, a once-weekly basal insulin marketed as Onswik, according to an announcement from drug manufacturer Eli Lilly. Designed as a supplementary treatment alongside proper diet and exercise, the newly approved therapy is intended to help adults manage type 2 diabetes by delivering consistent basal insulin levels continuously over a seven-day period.
According to statements from Eli Lilly, transitioning to a once-weekly formulation could significantly reduce the burden of daily care, cutting down routine injections by more than 300 times per year compared to traditional daily basal insulin regimens. Dr. Julio Rosenstock, lead investigator for the pivotal clinical trials from Velocity Clinical Research at Medical City in Dallas, noted that the therapy represents a meaningful step forward in simplifying daily routines for individuals who require insulin therapy.
The regulatory approval was supported by comprehensive findings from the QWINT phase III clinical trial program, which evaluated more than 3,400 individuals across four distinct international studies. In the QWINT-1 trial, which focused on insulin-naïve adults, efsitora showed non-inferiority in reducing glycated hemoglobin (HbA1c) levels at week 52 when measured against once-daily insulin glargine U-100. Similarly, the QWINT-2 trial demonstrated comparable efficacy and safety in insulin-naïve patients, including those concurrently utilizing GLP-1 receptor agonists.
Additional evaluations highlighted the therapy’s flexibility across different patient populations. In the QWINT-3 study, participants transitioning away from daily basal insulin achieved successful HbA1c reductions at 26 weeks matching the benchmark insulin degludec U-100. Furthermore, the QWINT-4 trial analyzed individuals managing more intricate regimens involving basal insulin alongside multiple daily mealtime insulin injections, demonstrating that efsitora achieved non-inferior blood sugar reductions compared to once-weekly and daily pairings.
While offering a less frequent dosing schedule, the medication maintains a safety profile comparable to existing daily basal insulins, according to the manufacturer. Common adverse events documented in clinical evaluations include hypoglycemia, hypersensitivity reactions, localized injection site reactions, lipodystrophy, pruritus, rashes, edema, and weight gain. Prescribing guidelines strictly advise against initiating treatment during active low blood sugar episodes and highlight potential risks associated with medication errors, low blood potassium, and fluid retention or heart failure if co-prescribed with specific diabetes medications like thiazolidinediones.
Efsitora becomes the second once-weekly basal insulin option cleared for adults with type 2 diabetes in the United States, following a previous regulatory clearance earlier in the year. Eli Lilly has indicated that the Onswik KwikPen will be distributed in the coming months, featuring two concentration options designed to accommodate varying patient needs.
Understanding Once-Weekly Insulin Options
Managing chronic conditions often involves navigating complex treatment schedules. The introduction of long-acting, weekly therapeutics addresses several key challenges faced by patients:
- Minimizing routine injection frequency to lessen daily treatment friction.
- Sustaining consistent therapeutic blood levels across a full week.
- Maintaining comparable blood sugar control relative to standard daily protocols.
Health authorities emphasize that the therapy is strictly indicated for adults with type 2 diabetes and is not cleared for pediatric populations or individuals managing type 1 diabetes due to elevated risks of severe hypoglycemia. Patients considering changes to their therapeutic regimen should consult qualified healthcare providers to discuss appropriate personalized management plans.
Source: MedPage Today
